Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Wednesday. The brokerage set a “hold” rating on the medical research company’s stock.

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a research note on Tuesday, February 25th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Price Performance

CTSO opened at $1.04 on Wednesday. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The stock’s 50 day simple moving average is $1.07 and its 200 day simple moving average is $1.05. The firm has a market cap of $56.87 million, a price-to-earnings ratio of -2.89 and a beta of 0.78. Cytosorbents has a 1 year low of $0.70 and a 1 year high of $1.61.

Institutional Trading of Cytosorbents

Large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its holdings in Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares in the last quarter. Skylands Capital LLC raised its stake in Cytosorbents by 1.0% in the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock worth $2,531,000 after buying an additional 26,195 shares in the last quarter. Millennium Management LLC purchased a new stake in Cytosorbents in the fourth quarter worth about $30,000. Northern Trust Corp boosted its position in Cytosorbents by 22.3% during the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after acquiring an additional 16,701 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Cytosorbents during the 4th quarter valued at approximately $99,000. Institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.